Skip to content

5E Advanced Materials, Inc. FEAM Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs

Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs at other companies

Esperion Therapeutics logo
Esperion TherapeuticsESPR
$18.15M-19.9%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$0
Castellum logo
CastellumCTM
$0-100%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
$0-100%
Contango Silver & Gold
 logo
Contango Silver & Gold CTGO
$52.44M+6,463%
Energy Fuels logo
Energy FuelsUUUU
$68.05M+1,538%

Other financials

Income statement

See full
Operating income-$12.3M-20.5%
Net income-$12.1M-330%
EPS (diluted)-$0.35+63.9%

Balance sheet

See full
Cash & equivalents$25.4M+530%
Total debt$123.0K-52.3%
Total equity$73.0M+10.2%
Total assets$78.1M+6.4%

Cash flow

See full
Operating cash flow-$4.3M+25.5%
CapEx$4.3M+4,563%
Free cash flow-$8.6M-47.8%

Valuation

See full
Market cap$57.71M-19.1%
Enterprise value$32.44M-52.6%

Returns & leverage

See full
Return on equity-62.4%-12.3pp
Debt / equity0.0×
Current ratio6.5×+5.8×

Where this comes from

Reported directly by 5E Advanced Materials, Inc. in its filing.

Tagged under the XBRL concept feam:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts.

The official record: 5E Advanced Materials, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about 5E Advanced Materials, Inc.'s proceeds from issuance of common stock and warrants net of issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 5E Advanced Materials, Inc.'s proceeds from issuance of common stock and warrants net of issuance costs?
5E Advanced Materials, Inc. (FEAM) reported proceeds from issuance of common stock and warrants net of issuance costs of $33.61M in Q1 2026.
What does proceeds from issuance of common stock and warrants net of issuance costs mean?
This represents the net cash received from the sale of equity securities and warrants to investors, after accounting for issuance costs. It is a critical measure of the company's ability to raise capital through dilution to fund operations or growth. Investors use this to evaluate the company's reliance on equity markets for financing.